Optimi Health Corp. · CSE:OPTI
Optimi Health — Investor Presentation (November 2022)
28 slides from Optimi Health's investor presentation, November 2022
Slide 1: Supplying natural, EU-GMP psilocybin and synthetic psychedelics
NOVEMBER 2022 Supplying natural, EU-GMP psilocybin and synthetic psychedelics * Optimi Health Corp. conducts business as Optimi Health. ** Optimi Health Corp. currently holds the Canadian Securities Exchange (CSE) ticker symbol of "OPTI". The company also holds ticker symbols with OTCQX Best Market
Slide 2: Forward-Looking Statements
FORWARD‐LOOKING STATEMENTS This presentation contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements
Slide 3: Our Story
Our Story cee ~ 7?“
Slide 4: Purpose, Vision and Promise
Purpose, Vision and Promise We produce scalable, natural mushroom formulations and synthetic psychedelics for transformational human experiences. To unlock the regenerative power of mushrooms, promote psychedelic science, and set the highest standard of trusted, GMP operational excellence in the wor
Slide 5: Our Values
Our Values Safety and Quality (EU-GMP). Research Led: Proprietary and open-source data sharing. Products and formulations powering transformational human experiences. Access, transparency, and compassion. Contributing to something bigger than Optimi.
Slide 6: A World in Crisis
A World in Crisis Opioid Addiction Mental Health Suicide Opioid use disorders We spend $2.5 More than 700 000 affect over 16 million trillion/year today people die due to people worldwide, over (direct and indirect) on suicide every year. 2.1 million in the United mental illness and are States, and
Slide 7: End-of-Life Distress
End-of-Life Distress Psychological suffering and existential distress are common among cancer patients approaching end-of-life. Psychedelic-assisted therapy can promote patients to safely surface concerns about mortality and face death, our “primordial fear” while simultaneously enabling resolution
Slide 8: The Cost of Doing Nothing
The Cost of Doing Nothing $1T The global cost in lost productivity from depression and anxiety disorders. $1.8T 80% The total global of patients with economic cost of advanced cancer smoking. are likely to suffer 36.3M 354M distressing thoughts around death. Total number of Number of adult persons w
Slide 9: Problem Solution
Problem Solution Grey Market Safe Supply Grey/black markets and a Access to an established, thriving underground safe supply of EU-GMP economy should concern all psilocybin and synthetic Canadians. psychedelics in regulated environments No safety or efficacy of is critical to building a designer / h
Slide 10: Value Proposition
IN-HOUSE LICENSED Value Capacity to produce a wide range of scalable, in- Fully licensed by Health Canada to grow and Proposition house formulations that distribute natural and puts us at the forefront of synthetic psychedelics to the commercial clinical trials, SAP, and manufacturing and supply res
Slide 11: Why Safe Supply?
Why Safe Supply? Therapists and patients looking to utilize psychedelics are unable to measure levels of natural psilocybin contained in the mushrooms. The grey and black markets are thriving online and in neighbourhoods across Canada. One way to combat this health and safety risk is to allow for li
Slide 12: Natural
Natural Properly sourced, pharmaceutical-grade psilocybin is the only way to know for sure that you’re giving your body the highest, purest, and most bioavailable form of an ingredient possible.
Slide 13: EU-GMP
Indoor Cultivation EU-GMP Our fruiting chambers are custom designed for biological efficiency and high-yield optimization, utilizing pure air exchange, compost, and high humidity controls to produce bio-sustainable fungi. Automation & Scale Our automated, integrated cultivation systems have been pro
Slide 14: Optimi Labs Inc.
Optimi Labs Inc. Optimi Labs Inc. is a wholly owned subsidiary of Optimi Health. Designed both for research into the company’s proprietary formulations and extraction methods. Utilized by clients and partners and approved companies to conduct investigations into molecular discovery with restricted p
Slide 15: Company Milestones
Company Milestones 35 + genetic strains of psilocybin. Largest harvest of legal natural psilocybin in Canadian history. Production and completion of MDMA (November 2022). First international distribution agreement (Avida Global). Human safety data and clinical trials confirming 25mg natural, encapsu
Slide 16: MDMA
MDMA Production of MDMA commenced Fall 2022 Substances added to Optimi's Dealer's Licence by Health Canada: N,N-Dimethyltryptamine (“DMT”); 3,4,5-trimethoxyphenethylamine (“Mescaline”); 2-(2-chlorophenyl)-2- (methylamino)cyclohexanone (“Ketamine”); Lysergic Acid Diethylamide (“LSD”); 1-(1-phenylcycl
Slide 17: Business Advantage
Business Advantage We are one of only 22 licensed dealers approved by Health Canada to produce psilocybin and synthetic psychedelic products. We have been approved by Health Canada to supply Canada's Special Access Program (SAP) and Clinical Trials. We specialize in global trade compliance and are f
Slide 18: Treatment Market Opportunities
Treatment Market Opportunities $63.99 B It is projected that by 2026, the global smoking cessation market will be valued at USD $63.99 billion. $47.2 B The global functional mushroom market is expected to grow at a compound annual growth rate of 9.5% from 2022 to 2028 to reach USD 47.2 billion. $24.
Slide 19: Global Addressable Market
Global Addressable Market expected to grow by 3.7% each year. Critical Financial Burdens of Mental Health: $16T cost of inaction on mental health crisis by 2030. $2.5T-$8.5T lost economic output due to mental, neurological and substance use disorders (World Bank). $2.5T direct and indirect economic
Slide 20: Nutraceuticals
Nutraceuticals Functional mushroom nutraceuticals are Organic ingredients. known for their wide range of benefits in areas such as immunity, anti-inflammation, mood, Full fruiting body mushrooms. and cognition. Formulated and made in Canada. Available at well.ca, Vitasave, Healthy Planet. Internati
Slide 21: Year of Commercialization
Facility construction Amendment to DL granted. completed. Expansion of on-site Request Health Canada site analytical laboratory. inspection. Acquire extensive catalog of Q Dealers License Inspection 1 3 psychedelic and functional Q completed by HC. mushroom genetics. Introduces Quality Assurance Com
Slide 22: Path to Revenue
Path to Revenue Commercialize Establish brand & market presence. Launch nutraceuticals (Optimi Life). Secure supply agreements. Complete/sell first grow. Exercise September 2022 Warrants. Maximize analytical lab. Manufacture MDMA for clinical trials & Operationalize SAP. Anticipate MDMA regulations
Slide 23: Financial Position and Private Placement
Financial Position as of July 30, 2022 Non-Brokered Private Placement October 11, 2022 Total Shares (As of 08 July 2022) 80,451,883 Total Shares @ $0.325 5,692,308 Cash $1,850,000 Warrant conversion @ $1.25 (As of 25 February 2023) 13,800,000 Assets Common Share purchase warrant exercisable at two (
Slide 24: Media coverage logos
y BENZINGA [JIANGUO yahoo? inance Gs y ¥ 7 ; 42s, CBC BRp rsyctevenic ALPHA Global> PSILOOYEIN? Bek 8b SES coLUMBIA NEWS be. EDIGITAL eee (C JOURNAL ey Investing HIGH TIMES HEDELIC SPOTLIGHT <<, VANCOUVER Network BUSINESS INTELLIGENCE FOR B.C.
Slide 25: Founders
Founders Dane Stevens - CMO & Director An entrepreneur with 12 years experience in international product sourcing, development, manufacturing, and quality control, Dane is the founder of multiple successful wholesale and retail DTC businesses, and is currently President of Cavalier Jewellers LTD. Af
Slide 26: Corporate Team
Corporate Team William (Bill J. Ciprick - CEO Over 25 years of Global experience across a wide array of industries in multifunctional organizations ranging from Fortune 500 corporations to small and medium-sized businesses. Bill graduated from UBC with a Bachelor Degree in Economics and has spent hi
Slide 27: Advisory Board & Directors
Advisory Board & Directors Chip Wilson Edward Safarik Dr. Azim Jamal Harley Pasternak Advisor Advisor Advisor Advisor Elfi Daniel-Ivad Jon Schintler Leigh Grant Mike Stier Licensing Advisor Independent Director Facility Advisor Director
Slide 28: Supplying natural, EU-GMP psilocybin and synthetic psychedelics
Supplying natural, EU-GMP psilocybin and synthetic psychedelics Email: investors@optimihealth.ca Phone: +1 (902) 880 6121 www.optimihealth.ca
Optimi Health — Investor Presentation (November 2022) on 6ix